Bayer's Financial Performance in Q4 and Full Year 2024

Bayer AG disclosed its financial outcomes for the fourth quarter and the full fiscal year of 2024, revealing a 1% decrease in Q4 sales to €11.7 billion and a 2.2% decline in annual sales to €46.6 billion. Despite these figures, the company witnessed an improvement in net income for the quarter, reporting €1.3 billion or €1.36 per share. However, the fiscal year concluded with a net loss of €2.9 billion or €2.99 per share.

Outlook for 2025 and Challenges Ahead

Looking forward, Bayer anticipates its net sales for the full year of 2025 to range between €45 and €47 billion. The company's report also highlights concerns over geopolitical uncertainties, including potential tariffs and foreign exchange fluctuations, which could impact future performance.

Reflecting on a Turbulent Year

"2024 was a challenging year for Bayer, characterized by volatile business dynamics. The Supervisory Board concentrated on strategic realignment and addressing critical issues, such as ongoing litigations in the United States, the company's high leverage ratio, and advancements in the pharmaceutical pipeline," the report stated, encapsulating a year of significant trials and adjustments for the pharmaceutical giant.